NASDAQ:NMRA Neumora Therapeutics (NMRA) Stock Price, News & Analysis → The biggest energy story ever? (From Porter & Company) (Ad) Free nmra Stock Alerts $9.23 +0.14 (+1.54%) (As of 02:52 PM ET) Add Compare Share Share Today's Range$8.90▼$9.4950-Day Range$9.06▼$19.2852-Week Range$8.82▼$21.00Volume358,343 shsAverage Volume474,197 shsMarket Capitalization$1.47 billionP/E RatioN/ADividend YieldN/APrice Target$22.57 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Neumora Therapeutics alerts: Email Address Neumora Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside145.3% Upside$22.57 Price TargetShort InterestBearish11.07% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.48) to ($1.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.68 out of 5 starsMedical Sector851st out of 919 stocksBiological Products, Except Diagnostic Industry141st out of 148 stocks 3.4 Analyst's Opinion Consensus RatingNeumora Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageNeumora Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted11.07% of the float of Neumora Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeumora Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.Change versus previous monthShort interest in Neumora Therapeutics has recently increased by 19.31%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeumora Therapeutics does not currently pay a dividend.Dividend GrowthNeumora Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NMRA. Previous Next 1.7 News and Social Media Coverage News SentimentNeumora Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Neumora Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for NMRA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neumora Therapeutics insiders have not sold or bought any company stock.Percentage Held by Institutions47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Neumora Therapeutics are expected to decrease in the coming year, from ($1.48) to ($1.53) per share.Price to Book Value per Share RatioNeumora Therapeutics has a P/B Ratio of 3.00. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingREAD THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”Click on Adam's shiny forehead for more details. About Neumora Therapeutics Stock (NASDAQ:NMRA)Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Read More NMRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NMRA Stock News HeadlinesApril 27, 2024 | msn.comParkinson’s UK invests £2.1 million in Neumora Therapeutics for preclinical testing of new Parkinson’s drugApril 27, 2024 | americanbankingnews.comNeumora Therapeutics (NASDAQ:NMRA) Reaches New 12-Month Low at $8.98May 1, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”April 27, 2024 | americanbankingnews.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 24, 2024 | finance.yahoo.comWe're Hopeful That Neumora Therapeutics (NASDAQ:NMRA) Will Use Its Cash WiselyApril 21, 2024 | americanbankingnews.comNeumora Therapeutics (NASDAQ:NMRA) Stock Price Down 4.6%April 18, 2024 | finance.yahoo.comBiotech Stock Roundup: REGN, SAGE, NMRA Down on Updates, ITCI Gains on Study SuccessApril 17, 2024 | msn.comNeumora Therapeutics (NMRA) Price Target Increased by 6.99% to 25.76May 1, 2024 | Banyan Hill Publishing (Ad)READ THIS – If You Missed Out On The AI BoomAdam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”April 17, 2024 | nasdaq.comNeumora Therapeutics Becomes Oversold (NMRA)April 16, 2024 | finanznachrichten.deNeumora Therapeutics, Inc.: Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 StudyApril 15, 2024 | bizjournals.comFDA pauses Watertown biotech’s schizophrenia trialApril 15, 2024 | finance.yahoo.comNeumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia DrugApril 15, 2024 | finance.yahoo.comWhy Is Neurology Focused-Neumora Therapeutics Shares Trading Lower On Monday?April 15, 2024 | marketwatch.comNeumora Shares Slide Premarket as FDA Puts Early Study of Schizophrenia Drug on HoldApril 15, 2024 | markets.businessinsider.comFDA Places Clinical Hold On Neumora's Phase 1 Study Of NMRA-266; Stock Tanks In Pre-MarketApril 15, 2024 | investorplace.comWhy Is Neumora Therapeutics (NMRA) Stock Down 25% Today?April 15, 2024 | globenewswire.comNeumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 StudyMarch 16, 2024 | finance.yahoo.comNMRA Apr 2024 17.500 putMarch 14, 2024 | finance.yahoo.cominstitutional investors of Neumora Therapeutics, Inc. (NASDAQ:NMRA) must be disappointed after last week's 20% dropMarch 13, 2024 | globenewswire.comNeumora Therapeutics to Participate at Stifel 2024 Virtual CNS DaysMarch 7, 2024 | investorplace.comNMRA Stock Earnings: Neumora Therapeutics Misses EPS for Q4 2023March 7, 2024 | finanznachrichten.deNeumora Therapeutics, Inc.: Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 7, 2024 | globenewswire.comNeumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateFebruary 15, 2024 | finance.yahoo.comNMRA Feb 2024 12.500 callFebruary 15, 2024 | finance.yahoo.comNMRA Feb 2024 15.000 putFebruary 8, 2024 | seekingalpha.comNeumora: Phase 3 MDD Readout In H2-24 Could Get Ball RollingSee More Headlines Receive NMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/01/2024Next Earnings (Estimated)6/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:NMRA CUSIPN/A CIK1885522 Webneumoratx.com Phone857-760-0900FaxN/AEmployees124Year FoundedN/APrice Target and Rating Average Stock Price Target$22.57 High Stock Price Target$31.00 Low Stock Price Target$13.00 Potential Upside/Downside+151.4%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio19.05 Quick Ratio19.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book2.93Miscellaneous Outstanding Shares159,453,000Free FloatN/AMarket Cap$1.43 billion OptionableOptionable BetaN/A 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Paul L. Berns (Age 57)Co-Founder & Executive Chairman Comp: $1.65MMr. Henry O. Gosebruch (Age 51)President, CEO & Director Comp: $3.33MMr. Jason G. Duncan (Age 50)Chief Legal Officer Comp: $315kMr. Robert Lenz M.D. (Age 53)Ph.D., Head of Research & Development Comp: $770.29kMs. Carol Suh (Age 34)Co-Founder & COO Dr. Robert Michael Poole FACP (Age 66)M.D., Co-Founder & Advisor Dr. Joshua Pinto Ph.D. (Age 39)Chief Financial Officer Comp: $876.64kMr. Michael Lee MilliganPrincipal Accounting OfficerDr. Rajesh Manchanda Ph.D. (Age 58)Chief Technical Operations Officer Mr. Nicholas Brandon Ph.D. (Age 50)Chief Scientific Officer More ExecutivesKey CompetitorsADMA BiologicsNASDAQ:ADMAInhibrxNASDAQ:INBX4D Molecular TherapeuticsNASDAQ:FDMTGinkgo BioworksNYSE:DNACidara TherapeuticsNASDAQ:CDTXView All CompetitorsInsiders & InstitutionsAddis & Hill IncBought 314,821 shares on 4/23/2024Ownership: 0.198%Windmill Hill Asset Management LtdBought 26,121 shares on 4/22/2024Ownership: 0.016%Avidity Partners Management LPBought 190,632 shares on 2/14/2024Ownership: 1.304%Tower Research Capital LLC TRC Bought 2,558 shares on 2/13/2024Ownership: 0.002%Amalgamated BankBought 1,709 shares on 2/6/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions NMRA Stock Analysis - Frequently Asked Questions Should I buy or sell Neumora Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neumora Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NMRA shares. View NMRA analyst ratings or view top-rated stocks. What is Neumora Therapeutics' stock price target for 2024? 7 analysts have issued 1-year target prices for Neumora Therapeutics' stock. Their NMRA share price targets range from $13.00 to $31.00. On average, they predict the company's stock price to reach $22.57 in the next twelve months. This suggests a possible upside of 145.3% from the stock's current price. View analysts price targets for NMRA or view top-rated stocks among Wall Street analysts. How have NMRA shares performed in 2024? Neumora Therapeutics' stock was trading at $17.05 on January 1st, 2024. Since then, NMRA stock has decreased by 46.0% and is now trading at $9.20. View the best growth stocks for 2024 here. When is Neumora Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, June 6th 2024. View our NMRA earnings forecast. How were Neumora Therapeutics' earnings last quarter? Neumora Therapeutics, Inc. (NASDAQ:NMRA) posted its earnings results on Thursday, March, 7th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.05. What ETFs hold Neumora Therapeutics' stock? ETFs with the largest weight of Neumora Therapeutics (NASDAQ:NMRA) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).ALPS Medical Breakthroughs ETF (SBIO). When did Neumora Therapeutics IPO? Neumora Therapeutics (NMRA) raised $250 million in an initial public offering (IPO) on Friday, September 15th 2023. The company issued 14,710,000 shares at a price of $17.00 per share. When did the company's lock-up period expire? Neumora Therapeutics' lock-up period expired on Wednesday, March 13th. Neumora Therapeutics had issued 14,710,000 shares in its initial public offering on September 15th. The total size of the offering was $250,070,000 based on an initial share price of $17.00. Since the end of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted. Who are Neumora Therapeutics' major shareholders? Neumora Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Addis & Hill Inc (0.20%) and Windmill Hill Asset Management Ltd (0.02%). Insiders that own company stock include Amgen Inc, Arch Venture Partners Xii, Llc, Henry O Gosebruch and Kristina Burow. View institutional ownership trends. How do I buy shares of Neumora Therapeutics? Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NMRA) was last updated on 5/1/2024 by MarketBeat.com Staff From Our PartnersAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Report😱 This phenomenon is smashing regular market gainsMillPubForget Nvidia. This is the future of AIPorter & CompanyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing4 coins to be the “Next Bitcoin”True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
